Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Titel:
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Powles, Thomas van der Heijden, Michiel S Castellano, Daniel Galsky, Matthew D Loriot, Yohann Petrylak, Daniel P Ogawa, Osamu Park, Se Hoon Lee, Jae-Lyun De Giorgi, Ugo Bögemann, Martin Bamias, Aristotelis Eigl, Bernhard J Gurney, Howard Mukherjee, Som D Fradet, Yves Skoneczna, Iwona Tsiatas, Marinos Novikov, Andrey Suárez, Cristina Fay, André P Duran, Ignacio Necchi, Andrea Wildsmith, Sophie He, Philip Angra, Natasha Gupta, Ashok K Levin, Wendy Bellmunt, Joaquim